Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...
The report, “Exploring sex and gender differences in the Alzheimer’s disease patient journey: A survey study” is based on a study of 142 participants across...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
Archan Ruparel presents the session providing an overview of the fundamentals of antitrust economics. The webinar is art of the ABA Antitrust Summer Series, a...